KV Pharmaceutical gets FDA OK to sell generic Tiazac for hypertension

By Elaine Rigoli

Tampa, Fla., Sept. 12 - KV Pharmaceutical Co. said it has received approval from the Food and Drug Administration to market six strengths of Diltiazem HCl ER capsules, a generic version of Forest Pharmaceuticals, Inc.'s Tiazac, through its wholly owned generic/non-branded subsidiary, Ethex Corp.

Ethex will begin shipments of all six strengths immediately.

Tiazac is indicated for the treatment of hypertension and angina. Total market sales for this product are roughly $160 million, according to a KV Pharmaceutical news release.

KV Pharmaceutical is a specialty pharmaceutical company based in St. Louis. It believes it is the first generic company to receive approval of the 420 mg strength dosage and thus expects to have six months exclusivity on this strength.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.